pegfilgrastim + plinabulin

Pegfilgrastim + plinabulin is an investigational combination therapy consisting of pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF) analog, and plinabulin, a novel small molecule immunomodulator and microtubule-binding agent. This combination is being developed primarily for the prevention of chemotherapy-induced neutropenia (CIN) in patients undergoing myelosuppressive chemotherapy regimens such as TAC (docetaxel, doxorubicin, cyclophosphamide). Pegfilgrastim stimulates the proliferation and differentiation of neutrophil precursors via G-CSF receptor agonism. Plinabulin binds to β-tubulin at a distinct site from other tubulin agents, activating GEF-H1 and promoting dendritic cell maturation and T-cell activation; it also reverses chemotherapy-induced blocks in neutrophil differentiation. The combination has demonstrated superior efficacy over pegfilgrastim alone in reducing rates of grade 4 neutropenia, decreasing bone pain associated with G-CSF therapy, improving absolute neutrophil count nadir values, reducing toxicity profiles, and enhancing patient quality-of-life[1][2][5][7][8].

Brand names

Neulasta